Clinical Trials
36 trialsA Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
MesoPDT
University Hospital, Lille
BIMES
Fundación GECP
Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma
H. Lee Moffitt Cancer Center and Research Institute
Feasibility of an Early Palliative Care Intervention for Metastatic Cancer Patients. A Phase 2 Study.
Azienda USL Reggio Emilia - IRCCS
NERO
University Hospital Southampton NHS Foundation Trust
RAMES
Gruppo Oncologico Italiano di Ricerca Clinica
Switch-Maintenance Gemcitabine After First-Line Chemotherapy In Patients With Malignant Pleural Mesothelioma
Ain Shams University
A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma
University of Chicago
A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)
University of Florida
PrE0505
PrECOG, LLC.
Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma
Eastern Cooperative Oncology Group
Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma
M.D. Anderson Cancer Center
MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma
Baylor College of Medicine
VIM
Wales Cancer Trials Unit
Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma.
Swiss Cancer Institute
Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma
Epizyme, Inc.
Olaparib in People With Malignant Mesothelioma
National Institutes of Health Clinical Center (CC)
MAPS2
Intergroupe Francophone de Cancerologie Thoracique
Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)
Bayer
Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma
University of Texas Southwestern Medical Center
ATREUS
Mario Negri Institute for Pharmacological Research
Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma
Columbia University
SIGNATURE
Novartis
18F-FSPG PET/CT for Cancer Patients on Therapy
Stanford University
UAB0901
University of Alabama at Birmingham
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Novartis
Tomotherapy Treatment for Mesothelioma
AHS Cancer Control Alberta
Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy
National Institutes of Health Clinical Center (CC)
Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity
Memorial Sloan Kettering Cancer Center
Phase II Study of Valproate and Doxorubicin in Malignant Mesothelioma
European Lung Cancer Working Party
An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma
AstraZeneca
Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma
Dana-Farber Cancer Institute
Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma
Istituto Clinico Humanitas
Study of Pemetrexed in Mesothelioma and Lung Cancer Patients With Fluid Around the Lungs or Abdomen
Eli Lilly and Company
Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma
Eli Lilly and Company